Addressing Canada's Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation.

Authors

Thomas Mullie, Anderson Chuck

Published in

Healthcare quarterly (Toronto, Ont.). Volume 29. Issue 2. Pages 29-36.

Abstract

The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada's life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada's poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada's health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act.

PMID:
42669639
Bibliographic data and abstract were imported from PubMed on 31 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.